Press Releases

Oct 12, 2012
Positive New Sativex® Data from Germany Presented at ECTRIMS that results of the MObility ImproVEments with Spasticity in Multiple Sclerosis (MOVE) 2 observational study performed in Germany, with 300 patients, showed that one month’s treatment with Sativex® (THC:CBD) oromucosal spray reduces
Oct 01, 2012
GW Appoints Chris Tovey as Chief Operating Officer London, UK; October 1st 2012: GW Pharmaceuticals plc (AIM: GWP) today announces the appointment, effective today, of Christopher John Tovey to the newly created position of Chief Operating Officer. Chris, aged 47, joins GW having gained a wealth of
Jun 22, 2012
German G-BA establishes positive additional benefit of Sativex® in Multiple Sclerosis Spasticity German G-BA establishes positive additional benefit of Sativex® in Multiple Sclerosis Spasticity German G-BA establishes positive additional benefit of Sativex® in Multiple Sclerosis Spasticity German
May 22, 2012
Third phase III Sativex® cancer pain trial commences GW’s cancer pain clinical programme is being wholly funded by Otsuka Pharmaceutical Co. Ltd, which has licensed the US commercialisation rights to this product. The trials are designed to obtain approval in this indication from the Food & Drug
May 22, 2012
Porton Down, UK, 22 May 2012: GW Pharmaceuticals plc (AIM: GWP, “GW” or “the Group”), the specialty pharmaceutical company focused on cannabinoid science, announces its interim results for the six months ended 31 March 2012. COMMERCIAL: STRONG PROGRESS Sativex ® in-market sales grow to £5.4m (H1